Ningbo Menovo Pharmaceutical Co (SHSE:603538) Total Operating Expense: ¥318 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
64 GF Score
Price ¥24.81
GF Value ¥16.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Total Operating Expense?

Ningbo Menovo Pharmaceutical Co SHSE:603538 +3.42% 64 Total Operating Expense is ¥318 Mil as of Mar. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 64/100 and a GF Value™ of ¥16.40 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Ningbo Menovo Pharmaceutical Co's Total Operating Expense for the three months ended in Mar. 2026 was ¥50 Mil. Ningbo Menovo Pharmaceutical Co's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ¥318 Mil.

Ningbo Menovo Pharmaceutical Co Total Operating Expense Related Terms

Ningbo Menovo Pharmaceutical Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co Total Operating Expense Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 281.00 341.37 291.18 302.82 326.00

Ningbo Menovo Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.33 82.62 78.05 106.99 50.25
SHSE:603538
64GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningbo Menovo Pharmaceutical Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥318 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ¥318 Mil mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Total Operating Expense of ¥318 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors.
Is Ningbo Menovo Pharmaceutical Co's Total Operating Expense too high?
Ningbo Menovo Pharmaceutical Co's current Total Operating Expense is ¥318 Mil. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Total Operating Expense compare to ZTS?
Ningbo Menovo Pharmaceutical Co's Total Operating Expense of ¥318 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. Ningbo Menovo Pharmaceutical Co's current Total Operating Expense is ¥318 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥16.40, compared to a current price of ¥24.81 — trading 51.3% above its estimated fair value. The current Total Operating Expense is ¥318 Mil. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Total Operating Expense is ¥318 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥24.81 is trading 51.3% above its estimated GF Value™ of ¥16.40. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Total Operating Expense: ¥318 Mil
  • GF Value™: ¥16.40 vs. price of ¥24.81 (51.3% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
64GF Score

Get the complete analysis for SHSE:603538

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.81
Price
¥16.40
GF Value